This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hollander, E. Articles by Reichman, D. Search for Related Content PubMed PubMed Citation Articles by Hollander, E. Articles by Reichman, D. Social Bookmarking                   What's this?

Venlafaxine in Children, Adolescents, and Young Adults With Autism Spectrum Disorders: An Open Retrospective Clinical Report

Department of Psychiatry and the Seaver Autism Research Center Mount Sinai School of Medicine New York, New York, e_hollander{at}smtplink.mssm.edu

Alicia Kaplan, MD

Department of Psychiatry and the Seaver Autism Research Center Mount Sinai School of Medicine New York, New York

Charles Cartwright, MD

Department of Psychiatry and the Seaver Autism Research Center Mount Sinai School of Medicine New York, New York

Daniel Reichman

Department of Psychiatry and the Seaver Autism Research Center Mount Sinai School of Medicine New York, New York

Autism is characterized by social deficits, communication and language impairments, narrow restricted interests, repetitive behaviors, inattention, and hyperactivity. While selective serotonin reuptake inhibitors have demonstrated efficacy in treating core symptoms of autism, norepinephrine reuptake inhibitors have demonstrated efficacy in symptoms of attention-deficit hyperactivity disorder (ADHD). An open, retrospective clinical study with venlafaxine evaluated its effect on core symptoms of autism as well as associated features of ADHD. Ten consecutive subjects meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), criteria for an autism spectrum disorder were treated with venlafaxine, initiated at 12.5 mg per day and adjusted on a flexible basis. Six of 10 completers were judged to be sustained treatment responders, by scoring 1 (very much improved) or 2 (much improved) on the Clinical Global Impressions improvement scale. Venlafaxine was effective in low dosages (mean, 24.37 mg/day; range, 6.25 to 50 mg/day) and was well tolerated. Improvement was noted in repetitive behaviors and restricted interests, social deficits, communication and language function, inattention, and hyperactivity. Controlled treatment trials with venlafaxine are warranted in autism spectrum disorders. (J Child Neurol 2000;15:132-135).

Journal of Child Neurology, Vol. 15, No. 2, 132-135 (2000)
DOI: 10.1177/088307380001500214


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				O. Dinca, M. Paul, and N. J. Spencer Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders J Psychopharmacol, September 1, 2005; 19(5): 521 - 532. [Abstract] [PDF]